EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 215 / Numéro 1-2 (2021) Biologie Aujourd’hui, 215 1-2 (2021) 45-57 References
Free Access
Issue
Biologie Aujourd’hui
Volume 215, Number 1-2, 2021
Page(s) 45 - 57
DOI https://doi.org/10.1051/jbio/2021006
Published online 16 août 2021
  • Annunziata, C.M., Davis, R.E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., Dave, S., Hurt, E.M., Tan, B., Zhao, H., Stephens, O., Santra, M., Williams, D.R., Dang, L., Barlogie, B., Shaughnessy, J.D. Jr, Kuehl, W.M., Staudt, L.M. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 12, 115-130. [CrossRef] [PubMed] [Google Scholar]
  • Babu, J.R., Geetha, T., Wooten, M.W. (2005). Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem, 94, 192-203. [CrossRef] [PubMed] [Google Scholar]
  • Balaji, V., Hoppe, T. (2020). Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly. F1000Res, 9. [Google Scholar]
  • Bang, S., Kaur, S., Kurokawa, M. (2019). Regulation of the p53 family proteins by the ubiquitin proteasomal pathway. Int J Mol Sci, 21, https://doi.org/10.3390/ijms21010261. [CrossRef] [Google Scholar]
  • Bard, J.A.M., Goodall, E.A., Greene, E.R., Jonsson, E., Dong, K.C., Martin, A. (2018). Structure and function of the 26S proteasome. Annu Rev Biochem, 87, 697-724. [CrossRef] [PubMed] [Google Scholar]
  • Bencivenga, D., Caldarelli, I., Stampone, E., Mancini, F.P., Balestrieri, M.L., Della Ragione, F., Borriello, A. (2017). p27(Kip1) and human cancers: a reappraisal of a still enigmatic protein. Cancer Lett, 403, 354-365. [CrossRef] [PubMed] [Google Scholar]
  • Boisson, B., Laplantine, E., Prando, C., Giliani, S., Israelsson, E., Xu, Z., Abhyankar, A., Israel, L., Trevejo-Nunez, G., Bogunovic, D., Cepika A.-M., MacDuff D., Chrabieh M., Hubeau M., Bajolle, F., Debré, M., Mazzolari, E., Vairo, D., Agou, F., Virgin, H.W., Bossuyt, X., Rambaud, C., Facchetti, F., Bonnet, D., Quartier, P., Fournet, J.-C., Pascual, V., Chaussabel, D., Notarangelo, L.D., Puel, A., Israël, A., Casanova, J.-L., Picard, C. (2012). Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol, 13, 1178-1186. [CrossRef] [PubMed] [Google Scholar]
  • Bulatov, E., Ciulli, A. (2015). Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem J, 467, 365-386. [CrossRef] [PubMed] [Google Scholar]
  • Carabet, L.A., Rennie, P.S., Cherkasov, A. (2018). Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches. Int J Mol Sci, 20, 120. [CrossRef] [Google Scholar]
  • Cardote, T.A.F., Gadd, M.S., Ciulli, A. (2017). Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex. Structure, 25, 901-911, e903. [CrossRef] [PubMed] [Google Scholar]
  • Ceccarelli, D.F., Tang, X., Pelletier, B., Orlicky, S., Xie, W., Plantevin, V., Neculai, D., Chou, Y.C., Ogunjimi, A., Al-Hakim, A., Varelas, X., Koszela, J., Wasney, G.A., Vedadi, M., Dhe-Paganon, S., Cox, S., Xu, S., Lopez-Girona, A., Mercurio, F., Wrana, J., Durocher, D., Meloche, S., Webb, D.R., Tyers, M., Sicheri, F. (2011). An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell, 145, 1075-1087. [CrossRef] [PubMed] [Google Scholar]
  • Cengiz Seval, G., Beksac, M. (2018). The safety of bortezomib for the treatment of multiple myeloma. Expert Opin Drug Saf, 17, 953-962. [CrossRef] [PubMed] [Google Scholar]
  • Clarke, B.A., Drujan, D., Willis, M.S., Murphy, L.O., Corpina, R.A., Burova, E., Rakhilin, S.V., Stitt, T.N., Patterson, C., Latres, E., Glass, D.J. (2007). The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab, 6, 376-385. [CrossRef] [PubMed] [Google Scholar]
  • Cohen, P., Strickson, S. (2017). The role of hybrid ubiquitin chains in the MyD88 and other innate immune signalling pathways. Cell Death Differ, 24, 1153-1159. [CrossRef] [PubMed] [Google Scholar]
  • Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L. (2012). Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J Cell Biol, 198, 575-589. [CrossRef] [PubMed] [Google Scholar]
  • Deshaies, R.J., Joazeiro, C.A. (2009). RING domain E3 ubiquitin ligases. Annu Rev Biochem, 78, 399-434. [CrossRef] [PubMed] [Google Scholar]
  • DiBello, A., Datta, A.B., Zhang, X., Wolberger, C. (2016). Role of E2-RING interactions in governing RNF4-mediated substrate ubiquitination. J Mol Biol, 428, 4639-4650. [CrossRef] [PubMed] [Google Scholar]
  • Doss-Pepe, E.W., Chen, L., Madura, K. (2005). Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J Biol Chem, 280, 16619-16624. [CrossRef] [PubMed] [Google Scholar]
  • Dove, K.K., Klevit, R.E. (2017). RING-between-RING E3 ligases: emerging themes amid the variations. J Mol Biol, 429, 3363-3375. [CrossRef] [PubMed] [Google Scholar]
  • Duffy, M.J., Synnott, N.C., O’Grady, S., Crown, J. (2020). Targeting p53 for the treatment of cancer. Semin Cancer Biol, S1044-579X(20)30160-7. [Google Scholar]
  • Einsele, H. (2014). Bortezomib. Recent results. Cancer Res, 201, 325–345. [Google Scholar]
  • Esposito, D., Koliopoulos, M.G., Rittinger, K. (2017). Structural determinants of TRIM protein function. Biochem Soc Trans, 45, 183-191. [CrossRef] [PubMed] [Google Scholar]
  • Fabris, L., Berton, S., Pellizzari, I., Segatto, I., D’Andrea, S., Armenia, J., Bomben, R., Schiappacassi, M., Gattei, V., Philips, M.R., Vecchione, A., Belletti, B., Baldassarre, G. (2015). p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. Proc Natl Acad Sci USA, 112, 13916-13921. [CrossRef] [Google Scholar]
  • French, M.E., Klosowiak, J.L., Aslanian, A., Reed, S.I., Yates, J.R., 3rd, Hunter, T. (2017). Mechanism of ubiquitin chain synthesis employed by a HECT domain ubiquitin ligase. J Biol Chem, 292, 10398-10413. [CrossRef] [PubMed] [Google Scholar]
  • Fu, L., Cui, C.P., Zhang, X., Zhang, L. (2020). The functions and regulation of Smurfs in cancers. Semin Cancer Biol, 67, 102-116. [CrossRef] [PubMed] [Google Scholar]
  • George, A.J., Hoffiz, Y.C., Charles, A.J., Zhu, Y., Mabb, A.M. (2018). A comprehensive atlas of E3 ubiquitin ligase mutations in neurological disorders. Front Genet, 9, 29. [CrossRef] [PubMed] [Google Scholar]
  • Glickman, M.H., Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev, 82, 373-428. [CrossRef] [PubMed] [Google Scholar]
  • Grasberger, B.L., Lu, T., Schubert, C., Parks, D.J., Carver, T.E., Koblish, H.K., Cummings, M.D., LaFrance, L.V., Milkiewicz, K.L., Calvo, R.R., Maguire, D., Lattanze, J., Franks, C.F., Zhao, S., Ramachandren, K., Bylebyl, G.R., Zhang, M., Manthey, C.L., Petrella, E.C., Pantoliano, M.W., Deckman, I.C., Spurlino, J.C., Maroney, A.C., Tomczuk, B.E., Molloy, C.J., Bone, R.F. (2005). Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem, 48, 909-912. [CrossRef] [PubMed] [Google Scholar]
  • Han, Z., Lu, J., Liu, Y., Davis, B., Lee, M.S., Olson, M.A., Ruthel, G., Freedman, B.D., Schnell, M.J., Wrobel, J.E., Reitz, A.B., Harty, R.N. (2014). Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J Virol, 88, 7294-7306. [CrossRef] [PubMed] [Google Scholar]
  • Harrigan, J.A., Jacq, X., Martin, N.M., Jackson, S.P. (2018). Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov, 17, 57-78. [CrossRef] [PubMed] [Google Scholar]
  • Hock, A.K., Vousden, K.H. (2014). The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta, 1843, 137-149. [CrossRef] [PubMed] [Google Scholar]
  • Hou, H., Sun, D., Zhang, X. (2019). The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int, 19, 216. [CrossRef] [PubMed] [Google Scholar]
  • Jain, A.K., Barton, M.C. (2010). Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther, 10, 665-672. [CrossRef] [PubMed] [Google Scholar]
  • Kaiser, S.E., Riley, B.E., Shaler, T.A., Trevino, R.S., Becker, C.H., Schulman, H., Kopito, R.R. (2011). Protein standard absolute quantification (PSAQ) method for the measurement of cellular ubiquitin pools. Nat Methods, 8, 691-696. [CrossRef] [PubMed] [Google Scholar]
  • Karbowski, M., Youle, R.J. (2011). Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation. Curr Opin Cell Biol, 23, 476-482. [CrossRef] [PubMed] [Google Scholar]
  • Kedar, V., McDonough, H., Arya, R., Li, H.H., Rockman, H.A., Patterson, C. (2004). Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA, 101, 18135-18140. [CrossRef] [Google Scholar]
  • Khatri, N., Man, H.Y. (2019). The autism and Angelman syndrome protein Ube3A/E6AP: the gene, E3 ligase ubiquitination targets and neurobiological functions. Front Mol Neurosci, 12, 109. [CrossRef] [PubMed] [Google Scholar]
  • Kim, H.T., Goldberg, A.L. (2017). The deubiquitinating enzyme Usp14 allosterically inhibits multiple proteasomal activities and ubiquitin-independent proteolysis. J Biol Chem, 292, 9830-9839. [CrossRef] [PubMed] [Google Scholar]
  • Kim, T., Bae, S.C., Kang, C. (2020). Synergistic activation of NF-kappaB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk. Arthritis Res Ther, 22, 93. [CrossRef] [PubMed] [Google Scholar]
  • Knipscheer, P., Raschle, M., Smogorzewska, A., Enoiu, M., Ho, T.V., Scharer, O.D., Elledge, S.J., Walter, J.C. (2009). The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science, 326, 1698-1701. [CrossRef] [PubMed] [Google Scholar]
  • Koliopoulos, M.G., Esposito, D., Christodoulou, E., Taylor, I.A., Rittinger, K. (2016). Functional role of TRIM E3 ligase oligomerization and regulation of catalytic activity. EMBO J, 35, 1204-1218. [CrossRef] [PubMed] [Google Scholar]
  • Komander, D., Clague, M.J., Urbe, S. (2009). Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol, 10, 550-563. [CrossRef] [PubMed] [Google Scholar]
  • Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., Andreeff, M. (2020). MDM2 inhibition: an important step forward in cancer therapy. Leukemia, 34, 2858-2874. [CrossRef] [PubMed] [Google Scholar]
  • Kontaxi, C., Piccardo, P., Gill, A.C. (2017). Lysine-directed post-translational modifications of tau protein in Alzheimer’s disease and related tauopathies. Front Mol Biosci, 4, 56. [CrossRef] [PubMed] [Google Scholar]
  • Kumar, B., Lecompte, K.G., Klein, J.M., Haas, A.L. (2010). Ser(120) of Ubc2/Rad6 regulates ubiquitin-dependent N-end rule targeting by E3{alpha}/Ubr1. J Biol Chem, 285, 41300-41309. [CrossRef] [PubMed] [Google Scholar]
  • Kumar, D., Kumar, P. (2019). Integrated mechanism of lysine 351, PARK2, and STUB1 in AbetaPP ubiquitination. J Alzheimers Dis, 68, 1125-1150. [CrossRef] [PubMed] [Google Scholar]
  • Kuo, C.L., Goldberg, A.L. (2017). Ubiquitinated proteins promote the association of proteasomes with the deubiquitinating enzyme Usp14 and the ubiquitin ligase Ube3c. Proc Natl Acad Sci USA, 114, E3404-E3413. [CrossRef] [Google Scholar]
  • Lagirand-Cantaloube, J., Offner, N., Csibi, A., Leibovitch, M.P., Batonnet-Pichon, S., Tintignac, L.A., Segura, C.T., Leibovitch, S.A. (2008). The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J, 27, 1266-1276. [CrossRef] [PubMed] [Google Scholar]
  • Lee, J.T., Gu, W. (2010). The multiple levels of regulation by p53 ubiquitination. Cell Death Differ, 17, 86-92. [CrossRef] [PubMed] [Google Scholar]
  • Lee, S., Challa-Malladi, M., Bratton, S.B., Wright, C.W. (2014). Nuclear factor-kappaB-inducing kinase (NIK) contains an amino-terminal inhibitor of apoptosis (IAP)-binding motif (IBM) that potentiates NIK degradation by cellular IAP1 (c-IAP1). J Biol Chem, 289, 30680-30689. [CrossRef] [PubMed] [Google Scholar]
  • Lehmann, A.R. (2003). DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie, 85, 1101-1111. [CrossRef] [PubMed] [Google Scholar]
  • Lemos, A., Gomes, A.S., Loureiro, J.B., Brandao, P., Palmeira, A., Pinto, M.M.M., Saraiva, L., Sousa, M.E. (2019). Synthesis, biological evaluation, and in silico studies of novel aminated xanthones as potential p53-activating agents. Molecules, 24, 1975. [CrossRef] [Google Scholar]
  • Li, H., Fang, Y., Niu, C., Cao, H., Mi, T., Zhu, H., Yuan, J., Zhu, J. (2018a). Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity. Proc Natl Acad Sci USA, 115, E9317-E9324. [CrossRef] [Google Scholar]
  • Li, X., Elmira, E., Rohondia, S., Wang, J., Liu, J., Dou, Q.P. (2018b). A patent review of the ubiquitin ligase system: 2015-2018. Expert Opin Ther Pat, 28, 919-937. [CrossRef] [PubMed] [Google Scholar]
  • Malecka, K.A., Fera, D., Schultz, D.C., Hodawadekar, S., Reichman, M., Donover, P.S., Murphy, M.E., Marmorstein, R. (2014). Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem Biol, 9, 1603-1612. [CrossRef] [PubMed] [Google Scholar]
  • Mattiroli, F., Vissers, J.H., van Dijk, W.J., Ikpa, P., Citterio, E., Vermeulen, W., Marteijn, J.A., Sixma, T.K. (2012). RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA damage signaling. Cell, 150, 1182-1195. [CrossRef] [PubMed] [Google Scholar]
  • Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., Ratcliffe, P.J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275. [CrossRef] [PubMed] [Google Scholar]
  • Metzger, M.B., Pruneda, J.N., Klevit, R.E., Weissman, A.M. (2014). RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim Biophys Acta, 1843, 47-60. [CrossRef] [PubMed] [Google Scholar]
  • Michelle, C., Vourc’h, P., Mignon, L., Andres, C.R. (2009). What was the set of ubiquitin and ubiquitin-like conjugating enzymes in the eukaryote common ancestor ? J Mol Evol, 68, 616-628. [CrossRef] [PubMed] [Google Scholar]
  • Montesinos, P., Beckermann, B.M., Catalani, O., Esteve, J., Gamel, K., Konopleva, M.Y., Martinelli, G., Monnet, A., Papayannidis, C., Park, A., Récher, C., Rodríguez-Veiga, R., Röllig, C., Vey, N., Wei, A.H., Yoon, S.-S., Fenaux, P. (2020). MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol, 16, 807-815. [CrossRef] [PubMed] [Google Scholar]
  • Mund, T., Lewis, M.J., Maslen, S., Pelham, H.R. (2014). Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. Proc Natl Acad Sci USA, 111, 16736-16741. [CrossRef] [Google Scholar]
  • Murayama, K., Kato-Murayama, M., Itoh, Y., Miyazono, K., Miyazawa, K., Shirouzu, M. (2020). Structural basis for inhibitory effects of Smad7 on TGF-beta family signaling. J Struct Biol, 212, 107661. [CrossRef] [PubMed] [Google Scholar]
  • Nakasone, M.A., Livnat-Levanon, N., Glickman, M.H., Cohen, R.E., Fushman, D. (2013). Mixed-linkage ubiquitin chains send mixed messages. Structure, 21, 727-740. [CrossRef] [PubMed] [Google Scholar]
  • Namuduri, A.V., Heras, G., Lauschke, V.M., Vitadello, M., Traini, L., Cacciani, N., Gorza, L., Gastaldello, S. (2020). Expression of SUMO enzymes is fiber type dependent in skeletal muscles and is dysregulated in muscle disuse. FASEB J, 34, 2269-2286. [CrossRef] [PubMed] [Google Scholar]
  • Nie, M., Boddy, M.N. (2016). Cooperativity of the SUMO and ubiquitin pathways in genome stability. Biomolecules, 6, 14. [CrossRef] [PubMed] [Google Scholar]
  • Offensperger, F., Muller, F., Jansen, J., Hammler, D., Gotz, K.H., Marx, A., Sirois, C.L., Chamberlain, S.J., Stengel, F., Scheffner, M. (2020). Identification of small-molecule activators of the ubiquitin ligase E6AP/UBE3A and Angelman syndrome-derived E6AP/UBE3A variants. Cell Chem Biol, 27, 1510-1520, e1516. [CrossRef] [PubMed] [Google Scholar]
  • Olzmann, J.A., Chin, L.S. (2008). Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy, 4, 85-87. [CrossRef] [PubMed] [Google Scholar]
  • Pancheri, E., Guglielmi, V., Wilczynski, G.M., Malatesta, M., Tonin, P., Tomelleri, G., Nowis, D., Vattemi, G. (2020). Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects. Cancers (Basel), 12, https://doi.org/10.3390/cancers12092540. [CrossRef] [Google Scholar]
  • Pao, K.C., Wood, N.T., Knebel, A., Rafie, K., Stanley, M., Mabbitt, P.D., Sundaramoorthy, R., Hofmann, K., van Aalten, D.M.F., Virdee, S. (2018). Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity. Nature, 556, 381-385. [CrossRef] [PubMed] [Google Scholar]
  • Park, C.W., Ryu, K.Y. (2014). Cellular ubiquitin pool dynamics and homeostasis. BMB Rep, 47, 475-482. [CrossRef] [PubMed] [Google Scholar]
  • Peris-Moreno, D., Cussonneau, L., Combaret, L., Polge, C., Taillandier, D. (2021). Ubiquitin ligases at the heart of skeletal muscle atrophy control. Molecules, 26, 407. [CrossRef] [Google Scholar]
  • Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., De Lucia, M., McGowan, E., Lewis, J., Prihar, G., Kim, J., Dillmann, W.H., Browne, S.E., Hall, A., Voellmy, R., Tsuboi, Y., Dawson, T.M., Wolozin, B., Hardy, J., Hutton, M. (2004). CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet, 13, 703-714. [CrossRef] [PubMed] [Google Scholar]
  • Pines, J. (2011). Cubism and the cell cycle: the many faces of the APC/C. Nat Rev Mol Cell Biol, 12, 427-438. [CrossRef] [PubMed] [Google Scholar]
  • Polge, C., Attaix, D., Taillandier, D. (2015). Role of E2-Ub-conjugating enzymes during skeletal muscle atrophy. Front Physiol, 6, 59. [CrossRef] [PubMed] [Google Scholar]
  • Polge, C., Heng, A.E., Jarzaguet, M., Ventadour, S., Claustre, A., Combaret, L., Bechet, D., Matondo, M., Uttenweiler-Joseph, S., Monsarrat, B., Attaix, D., Taillandier, D. (2011). Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J, 25, 3790-3802. [CrossRef] [PubMed] [Google Scholar]
  • Polge, C., Uttenweiler-Joseph, S., Leulmi, R., Heng, A.E., Burlet-Schiltz, O., Attaix, D., Taillandier, D. (2013). Deciphering the ubiquitin proteome: limits and advantages of high throughput global affinity purification-mass spectrometry approaches. Int J Biochem Cell Biol, 45, 2136-2146. [CrossRef] [PubMed] [Google Scholar]
  • Polge, C., Cabantous, S., Deval, C., Claustre, A., Hauvette, A., Bouchenot, C., Aniort, J., Bechet, D., Combaret, L., Attaix, D., Taillandier, D. (2018). A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate. J Cachexia Sarcopenia Muscle, 9, 129-145. [CrossRef] [PubMed] [Google Scholar]
  • Quartararo, A.J., Gates, Z.P., Somsen, B.A., Hartrampf, N., Ye, X., Shimada, A., Kajihara, Y., Ottmann, C., Pentelute, B.L. (2020). Ultra-large chemical libraries for the discovery of high-affinity peptide binders. Nat Commun, 11, 3183. [CrossRef] [PubMed] [Google Scholar]
  • Quirit, J.G., Lavrenov, S.N., Poindexter, K., Xu, J., Kyauk, C., Durkin, K.A., Aronchik, I., Tomasiak, T., Solomatin, Y.A., Preobrazhenskaya, M.N., Firestone, G.L. (2017). Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells. Biochem Pharmacol, 127, 13-27. [CrossRef] [PubMed] [Google Scholar]
  • Rizk, J., Kaplinsky, J., Agerholm, R., Kadekar, D., Ivars, F., Agace, W.W., Wong, W.W., Szucs, M.J., Myers, S.A., Carr, S.A., Waisman, A., Bekiaris, V. (2019). SMAC mimetics promote NIK-dependent inhibition of CD4(+) TH17 cell differentiation. Sci Signal, 12, https://doi.org/10.1126/scisignal.aaw3469. [CrossRef] [PubMed] [Google Scholar]
  • Rotin, D., Kumar, S. (2009). Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol, 10, 398-409. [CrossRef] [PubMed] [Google Scholar]
  • Rubio, I., Rodriguez-Navarro, J.A., Tomas-Zapico, C., Ruiz, C., Casarejos, M.J., Perucho, J., Gomez, A., Rodal, I., Lucas, J.J., Mena, M.A., García de Yébenes, J. (2009). Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. Brain Res, 1281, 91-100. [CrossRef] [PubMed] [Google Scholar]
  • Rui, L., Yuan, M., Frantz, D., Shoelson, S., White, M.F. (2002). SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem, 277, 42394-42398. [CrossRef] [PubMed] [Google Scholar]
  • Sarcevic, B., Mawson, A., Baker, R.T., Sutherland, R.L. (2002). Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation. EMBO J, 21, 2009-2018. [CrossRef] [PubMed] [Google Scholar]
  • Scott, K., Hayden, P.J., Will, A., Wheatley, K., Coyne, I. (2016). Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev, 4, CD010816. [PubMed] [Google Scholar]
  • Seth, B., Yadav, A., Agarwal, S., Tiwari, S.K., Chaturvedi, R.K. (2017). Inhibition of the transforming growth factor-beta/SMAD cascade mitigates the anti-neurogenic effects of the carbamate pesticide carbofuran. J Biol Chem, 292, 19423-19440. [CrossRef] [PubMed] [Google Scholar]
  • Sharma, A., Alswillah, T., Singh, K., Chatterjee, P., Willard, B., Venere, M., Summers, M.K., Almasan, A. (2018). USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy, 14, 1976-1990. [CrossRef] [PubMed] [Google Scholar]
  • Skalniak, L., Surmiak, E., Holak, T.A. (2019). A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018). Expert Opin Ther Pat, 29, 151-170. [CrossRef] [PubMed] [Google Scholar]
  • Sluimer, J., Distel, B. (2018). Regulating the human HECT E3 ligases. Cell Mol Life Sci, 75, 3121-3141. [CrossRef] [PubMed] [Google Scholar]
  • Song, J.J., Szczepanski, M.J., Kim, S.Y., Kim, J.H., An, J.Y., Kwon, Y.T., Alcala, M.A. Jr., Bartlett, D.L., Lee, Y.J. (2010). c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal, 22, 553-563. [CrossRef] [PubMed] [Google Scholar]
  • Song, R., Peng, W., Zhang, Y., Lv, F., Wu, H.K., Guo, J., Cao, Y., Pi, Y., Zhang, X., Jin, L., Zhang, M, Jiang, P, Liu, F, Meng, S, Zhang, X, Jiang, P, Cao, CM, Xiao, RP. (2013). Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature, 494, 375-379. [CrossRef] [PubMed] [Google Scholar]
  • Soss, S.E., Klevit, R.E., Chazin, W.J. (2013). Activation of UbcH5c∼Ub is the result of a shift in interdomain motions of the conjugate bound to U-box E3 ligase E4B. Biochemistry, 52, 2991-2999. [CrossRef] [PubMed] [Google Scholar]
  • Spratt, D.E., Martinez-Torres, R.J., Noh, Y.J., Mercier, P., Manczyk, N., Barber, K.R., Aguirre, J.D., Burchell, L., Purkiss, A., Walden, H., Shaw, G.S. (2013). A molecular explanation for the recessive nature of parkin-linked Parkinson’s disease. Nat Commun, 4, 1983. https://doi.org/10.1038/ncomms2983. [CrossRef] [PubMed] [Google Scholar]
  • Sugeno, N., Hasegawa, T., Tanaka, N., Fukuda, M., Wakabayashi, K., Oshima, R., Konno, M., Miura, E., Kikuchi, A., Baba, T., Anan, T., Nakao, M., Geisler, S., Aoki, M., Takeda, A. (2014). Lys-63-linked ubiquitination by E3 ubiquitin ligase Nedd4-1 facilitates endosomal sequestration of internalized alpha-synuclein. J Biol Chem, 289, 18137-18151. [CrossRef] [PubMed] [Google Scholar]
  • Taillandier, D., Polge, C. (2019). Skeletal muscle atrogenes: From rodent models to human pathologies. Biochimie, 166, 251-269. [CrossRef] [PubMed] [Google Scholar]
  • Takedachi, A., Saijo, M., Tanaka, K. (2010). DDB2 complex-mediated ubiquitylation around DNA damage is oppositely regulated by XPC and Ku and contributes to the recruitment of XPA. Mol Cell Biol, 30, 2708-2723. [CrossRef] [PubMed] [Google Scholar]
  • Tan, W., van Twest, S., Leis, A., Bythell-Douglas, R., Murphy, V.J., Sharp, M., Parker, M.W., Crismani, W., Deans, A.J. (2020). Monoubiquitination by the human Fanconi anemia core complex clamps FANCI:FANCD2 on DNA in filamentous arrays. Elife, 9, https://doi.org/10.7554/eLife.54128. [PubMed] [Google Scholar]
  • Tian, M., Zeng, T., Liu, M., Han, S., Lin, H., Lin, Q., Li, L., Jiang, T., Li, G., Lin, H., Jiang, T., Li, G., Lin, H., Zhang, T., Kang, Q., Deng, X., Wang, H.-R. (2019). A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases. J Biol Chem, 294, 2880-2891. [CrossRef] [PubMed] [Google Scholar]
  • Tintignac, L.A., Lagirand, J., Batonnet, S., Sirri, V., Leibovitch, M.P., Leibovitch, S.A. (2005). Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem, 280, 2847-2856. [CrossRef] [PubMed] [Google Scholar]
  • Tomko, R.J. Jr., Hochstrasser, M. (2013). Molecular architecture and assembly of the eukaryotic proteasome. Annu Rev Biochem, 82, 415-445. [CrossRef] [PubMed] [Google Scholar]
  • Trotman, L.C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N.P., Carver, B.S., Cordon-Cardo, C., Erdjument-Bromage, H., Tempst, P, Chi, SG, Kim, HJ, Misteli, T, Jiang, X, Pandolfi, PP. (2007). Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell, 128, 141-156. [CrossRef] [PubMed] [Google Scholar]
  • van Wijk, S.J., Timmers, H.T. (2010). The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J, 24, 981-993. [CrossRef] [PubMed] [Google Scholar]
  • Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., Liu, E.A. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-848. [CrossRef] [PubMed] [Google Scholar]
  • Velasco, R., Alberti, P., Bruna, J., Psimaras, D., Argyriou, A.A. (2019). Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst, 24(Suppl 2), S52-S62. [CrossRef] [PubMed] [Google Scholar]
  • Wade, M., Li, Y.C., Wahl, G.M. (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer, 13, 83-96. [CrossRef] [PubMed] [Google Scholar]
  • Wagner, S.A., Beli, P., Weinert, B.T., Nielsen, M.L., Cox, J., Mann, M., Choudhary, C. (2011). A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics, 10, M111 013284. [CrossRef] [PubMed] [Google Scholar]
  • Walsh, M.C., Kim, G.K., Maurizio, P.L., Molnar, E.E., Choi, Y. (2008). TRAF6 autoubiquitinylation-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL. PLoS One, 3, e4064. [CrossRef] [PubMed] [Google Scholar]
  • Wang, B., Merillat, S.A., Vincent, M., Huber, A.K., Basrur, V., Mangelberger, D., Zeng, L., Elenitoba-Johnson, K., Miller, R.A., Irani, D.N., Andrzej A., Dlugosz, A.A., Schnell, S., Scaglione, K.M., Paulson, H.L. (2016). Loss of the ubiquitin-conjugating enzyme UBE2W results in susceptibility to early postnatal lethality and defects in skin, immune, and male reproductive systems. J Biol Chem, 291, 3030-3042. [CrossRef] [PubMed] [Google Scholar]
  • Wang, M., Guo, L., Wu, Q., Zeng, T., Lin, Q., Qiao, Y., Wang, Q., Liu, M., Zhang, X., Ren, L, Zhang, S., Pei, Y., Yin, Z., Ding, F., Wang, H.R. (2014). ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance. Nat Commun, 5, 4901. [CrossRef] [PubMed] [Google Scholar]
  • Wang, S., Adrianto, I., Wiley, G.B., Lessard, C.J., Kelly, J.A., Adler, A.J., Glenn, S.B., Williams, A.H., Ziegler, J.T., Comeau, M.E., Marion, M.C. Wakeland, B.E., Liang, C., Kaufman, K.M., Guthridge, J.M., Alarcón-Riquelme, M.E., BIOLUPUS and GENLES Networks ; Alarcón, G.S., Anaya, J.-M., Bae, S.-C., Kim, J.-H., Joo, Y.B., Boackle, S.A., Brown, E.E., Petri, M.A., Ramsey-Goldman, R., Reveille, J.D., Vilá, L.M., Criswell, L.A., Edberg, J.C., Freedman, B.I., Gilkeson, G.S., Jacob, C.O., James, J.A., Kamen, D.L., Kimberly, R.P., Martin, J., Merrill, J.T., Niewold, T.B., Pons-Estel, B.A., Scofield, R.H., Stevens, A.M., Tsao, B.P., Vyse, T.J., Langefeld, C.D., Harley, J.B., Wakeland, E.K., Moser, K.L., Montgomery, C.G., Gaffney, P.M. (2012). A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun, 13, 380-387. [CrossRef] [PubMed] [Google Scholar]
  • Wang, S., Zhao, Y., Aguilar, A., Bernard, D., Yang, C.Y. (2017). Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges. Cold Spring Harb Perspect Med, 7(5): a026245. [CrossRef] [PubMed] [Google Scholar]
  • Wang, Y., Argiles-Castillo, D., Kane, E.I., Zhou, A., Spratt, D.E. (2020). HECT E3 ubiquitin ligases – Emerging insights into their biological roles and disease relevance. J Cell Sci, 133, https://doi.org/10.1242/jcs.228072. [Google Scholar]
  • Watt, J.E., Hughes, G.R., Walpole, S., Monaco, S., Stephenson, G.R., Bulman Page, P.C., Hemmings, A.M., Angulo, J., Chantry, A. (2018). Discovery of small molecule WWP2 ubiquitin ligase inhibitors. Chemistry, 24, 17677-17680. [CrossRef] [PubMed] [Google Scholar]
  • Weber, J., Polo, S., Maspero, E. (2019). HECT E3 ligases: a tale with multiple facets. Front Physiol, 10, 370. [CrossRef] [PubMed] [Google Scholar]
  • Wenzel, D.M., Stoll, K.E., Klevit, R.E. (2011). E2s: structurally economical and functionally replete. Biochem J, 433, 31-42. [CrossRef] [PubMed] [Google Scholar]
  • Witt, A., Vucic, D. (2017). Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling. Cell Death Differ, 24, 1160-1171. [CrossRef] [PubMed] [Google Scholar]
  • Wu, K., Chong, R.A., Yu, Q., Bai, J., Spratt, D.E., Ching, K., Lee, C., Miao, H., Tappin, I., Hurwitz, J., Zheng, N., Shaw, G.S., Sun, Y., Felsenfeld, D.P., Sanchez, R., Jun-Zheng, N., Pan, Z.-Q. (2016). Suramin inhibits cullin-RING E3 ubiquitin ligases. Proc Natl Acad Sci USA, 113, E2011-2018. [CrossRef] [Google Scholar]
  • Wu, W., Koike, A., Takeshita, T., Ohta, T. (2008). The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Div, 3, 1. [CrossRef] [PubMed] [Google Scholar]
  • Xia, Y., Pao, G.M., Chen, H.W., Verma, I.M., Hunter, T. (2003). Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem, 278, 5255-5263. [CrossRef] [PubMed] [Google Scholar]
  • Yang, W.L., Zhang, X., Lin, H.K. (2010). Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene, 29, 4493-4503. [CrossRef] [PubMed] [Google Scholar]
  • Zhang, X., Linder, S., Bazzaro, M. (2020a). Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers. Cancers (Basel), 12, 902. [Google Scholar]
  • Zhang, X., Shi, S., Su, Y., Yang, X., He, S., Yang, X., Wu, J., Zhang, J., Rao, F. (2020b). Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat. J Biol Chem, 295, 10281-10292. [PubMed] [Google Scholar]
  • Zheng, N., Shabek, N. (2017). Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem, 86, 129-157. [PubMed] [Google Scholar]
  • Zhu, X., Li, T., Niu, X., Chen, L., Ge, C. (2020). Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer. Oncol Lett, 20, 44. [PubMed] [Google Scholar]
  • Zinngrebe, J., Montinaro, A., Peltzer, N., Walczak, H. (2014). Ubiquitin in the immune system. EMBO Rep, 15, 28-45. [PubMed] [Google Scholar]
  • Zucchelli, S., Marcuzzi, F., Codrich, M., Agostoni, E., Vilotti, S., Biagioli, M., Pinto, M., Carnemolla, A., Santoro, C., Gustincich, S., Persichetti, F. (2011). Tumor necrosis factor receptor-associated factor 6 (TRAF6) associates with huntingtin protein and promotes its atypical ubiquitination to enhance aggregate formation. J Biol Chem, 286, 25108-25117. [PubMed] [Google Scholar]
  • Zuo, C., Sheng, X., Ma, M., Xia, M., Ouyang, L. (2016). ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget, 7, 74393-74409. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.